Switch to Donna E. Hogge's research page...

2006

1. Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res. 12(4):1284-91. (2006).
    [View Abstract - PubMed 16489085]  Request Paper

2004

2. Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res 28(11):1221-6. (2004).
    [View Abstract - PubMed 15380349]  Request Paper

3. Nicolini FE, Cashman JD, Hogge DE, Humphries RK, Eaves CJ. NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. Leukemia 18(2):341-7. (2004).
    [View Abstract - PubMed 14628073]  Request Paper

4. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ, Tsang P, Hogge DE. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 103(1):333-9. (2004).
    [View Abstract - PubMed 12958065]  Request Paper

5. Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif 33(1):123-33. (2004).
    [View Abstract - PubMed 14680969]  Request Paper

2003

6. Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, Hogge DE. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17(4):760-3. (2003).
    [View Abstract - PubMed 12682634]  Request Paper

7. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101(8):3142-9. (2003).
    [View Abstract - PubMed 12468427]  Request Paper

2002

8. Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 62(6):1730-6. (2002).
    [View Abstract - PubMed 11912147]  Request Paper

9. Guan Y, Ralph S, Hogge DE. Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Exp Hematol 30(7):721-8. (2002).
    [View Abstract - PubMed 12135669]  Request Paper

2001

10. Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 97(12):3882-9. (2001).
     [View Abstract - PubMed 11389030]  Request Paper

2000

11. Feuring-Buske M, Frankel A, Gerhard B, Hogge D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol 28(12):1390-400. (2000).
     [View Abstract - PubMed 11146161]  Request Paper

12. Guan Y, Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 14(12):2135-41. (2000).
     [View Abstract - PubMed 11187903]  Request Paper

13. Hogge DE, Lambie K, Sutherland HJ, Benny WB, Dalal B, Currie C, Barnett MJ, Eaves AC, Eaves CJ. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Bone Marrow Transplant 25(6):589-98. (2000).
     [View Abstract - PubMed 10734292]  Request Paper

1999

14. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice Blood 94(5):1761-72 (1999).
     Request Paper

15. Ailles LE, Humphries RK, Thomas TE, Hogge DE. Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice Exp Hematol. 27(11):1609-20 (1999).
     Request Paper

16. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13(5):687-98. (1999).
     [View Abstract - PubMed 10374871]  Request Paper

1998

17. Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ & Frankel AE. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood 92: 589-595 (1998).
     Request Paper

1997

18. Ailles LE, Gerhard B & Hogge DE. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 90: 2555-2564 (1997).
     Request Paper

19. Hogge D, Fanning S, Bockhold K, Petzer A, Lambie K, Lansdorp P, Eaves A & Eaves C. Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. Br J Haematol 96: 790-800 (1997).
     Request Paper

1996

20. Hogge DE, Lansdorp PM, Reid D, Gerhard B & Eaves CJ. Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor. Blood 88: 3765-3773 (1996).
     Request Paper

1994

21. Thacker JD & Hogge DE. Cytokine-dependent engraftment of human myeloid leukemic cell lines in immunosuppressed nude mice. Leukemia 8: 871-877 (1994).
     Request Paper

1991

22. Otsuka T, Thacker JD, Eaves CJ & Hogge DE. Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells. J Clin Invest 88: 417-422 (1991).
     Request Paper